Related Experiment Video
Updated: Sep 10, 2025
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Fecal and Clinical Profiles of Dogs With Chronic Enteropathies Treated With Bile Acid Sequestrants for 5-47 Months: A
Linda Toresson1,2, Amanda B Blake1, Chi-Hsuan Sung1
1Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA.
Background:
Bile acid (BA) malabsorption and BA diarrhea (BAD) are prevalent but underdiagnosed conditions in people with chronic diarrhea of multiple causes. Recent studies have shown BA dysmetabolism in dogs with chronic enteropathies (CE).
Objective:
Describe canine inflammatory bowel disease activity index (CIBDAI), dysbiosis index (DI) and fecal BA concentrations in healthy dogs and dogs with refractory or partially immunosuppressive-responsive CE or CE dogs requiring high doses of corticosteroids, treated with BA sequestrants (BAS).
Animals:
Twenty-four CE dogs and 18 healthy dogs.
Methods:
Retrospective case series. Dogs with CE were treated with BAS as adjunctive treatment. Fecal BA was analyzed using liquid chromatography-tandem mass spectrometry. Fecal microbiota was assessed using DI. Response to treatment was defined as a decrease in CIBDAI category.
Results:
Sixteen of 24 dogs improved clinically after BAS treatment (cholestyramine, 44-133 mg/kg q12h; colesevelam, 7-24 mg/kg q12h; colestipole, 26 mg/kg q24h). Duration of treatment was 5-47 months. Median (range) CIBDAI decreased from 6.5 (4-13) to 3 (2-5) in responders. At baseline, responders had a higher median (range) percentage of fecal unconjugated primary BAs (93 [1-100]) versus non-responders (2.5 [0-95]) and healthy dogs (1.5 [0-19]). Dysbiosis index (median [range]) was higher in responders (4.2 [-4.7 to 9.0]) versus non-responders (-0.1 [-1.5 to 5.7]) and healthy dogs (-4.5 [-6.4 to -0.2]).
Conclusions And Clinical Importance:
Treatment with BAS as adjunctive treatment potentially may benefit some dogs with nonresponsive or partially immunosuppressive-responsive enteropathy or CE dogs requiring high doses of corticosteroids.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment: